Milestone Pharmaceuticals (NASDAQ:MIST) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $25.00 target price on the stock.

Separately, Piper Sandler decreased their price target on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, March 5th.

Milestone Pharmaceuticals Stock Down 2.0 %

Shares of MIST stock opened at $1.50 on Thursday. The stock’s fifty day moving average price is $1.70 and its 200 day moving average price is $1.88. Milestone Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $4.14. The company has a market cap of $79.89 million, a price-to-earnings ratio of -1.20 and a beta of 1.77. The company has a debt-to-equity ratio of 1.27, a current ratio of 22.75 and a quick ratio of 22.75.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). On average, research analysts expect that Milestone Pharmaceuticals will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BML Capital Management LLC raised its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 442,352 shares of the company’s stock after purchasing an additional 169,852 shares during the quarter. Milestone Pharmaceuticals accounts for approximately 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. BML Capital Management LLC owned 1.32% of Milestone Pharmaceuticals worth $739,000 as of its most recent SEC filing. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.